Viral Vaccines

• 

  Subject Areas on Research

  • A Southeastern Cancer Study Group phase I/II trial with vaccinia melanoma oncolysates. 
  • A glial fibrillary acidic protein-expressing and tumorigenic cell line derived from an avian sarcoma virus-induced rat astrocytoma. 
  • A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice. 
  • A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. 
  • A vaccine against CCR5 protects a subset of macaques upon intravaginal challenge with simian immunodeficiency virus SIVmac251. 
  • AIDS vaccines. 
  • AIDS vaccines: progress and unmet challenges. 
  • ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. 
  • Adenovirus vaccine immunotherapy targeting WT1-expressing tumors. 
  • Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. 
  • Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. 
  • Adult adenovirus infections: loss of orphaned vaccines precipitates military respiratory disease epidemics. For the Adenovirus Surveillance Group. 
  • An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains. 
  • Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. 
  • Approaches to HIV vaccine design. 
  • Beyond Oncolytics: E1B55K-Deleted Adenovirus as a Vaccine Delivery Vector. 
  • Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition. 
  • Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial. 
  • Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins. 
  • Childhood vaccine development: an overview. 
  • Chimeric Sindbis/eastern equine encephalitis vaccine candidates are highly attenuated and immunogenic in mice. 
  • Chimeric alphavirus vaccine candidates for chikungunya. 
  • Codelivery of Envelope Protein in Alum with MVA Vaccine Induces CXCR3-Biased CXCR5+ and CXCR5- CD4 T Cell Responses in Rhesus Macaques. 
  • Combination live enteric virus vaccines. 
  • Combined systemic and mucosal immunization with microsphere-encapsulated inactivated simian immunodeficiency virus elicits serum, vaginal, and tracheal antibody responses in female rhesus macaques. 
  • Comparison of the genomes of the wild-type French viscerotropic strain of yellow fever virus with its vaccine derivative French neurotropic vaccine. 
  • Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. 
  • Complement-mediated, infection-enhancing antibodies in plasma from vaccinated macaques before and after inoculation with live simian immunodeficiency virus. 
  • Cost-effectiveness of a potential vaccine for human papillomavirus. 
  • Current status and strategies for vaccines against diseases induced by human T-cell lymphotropic retroviruses (HTLV-I, -II, -III). 
  • DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. 
  • DNA vaccines and immunity to herpes simplex virus. 
  • DNA vaccines. 
  • DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies. 
  • Detection of anti-human cell antibodies in sera from macaques immunized with whole inactivated virus. 
  • Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network. 
  • Development of a vaccine for the prevention of AIDS, a critical appraisal. 
  • Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques. 
  • Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity. 
  • Enhanced type 1 immunity after secondary viral challenge in mice primed as neonates. 
  • Enteroviruses in the early 21st century: new manifestations and challenges. 
  • Evaluating human papillomavirus vaccination programs. 
  • GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. 
  • HIV antibodies and vaccine design. 
  • HIV immunization. Fresh pathways to follow. 
  • HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers. 
  • HLA class I serotypes and cytotoxic T-lymphocyte responses among human immunodeficiency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp120 or oligomeric gp160 protein boosting. 
  • Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. 
  • Hepatitis B surface antigen could harbour the infective agent of AIDS. 
  • Hepatitis B virus vaccine. An analysis of its potential use in medical workers. 
  • High Doses of GM-CSF Inhibit Antibody Responses in Rectal Secretions and Diminish Modified Vaccinia Ankara/Simian Immunodeficiency Virus Vaccine Protection in TRIM5α-Restrictive Macaques. 
  • Immune mechanisms responsible for vaccination against and clearance of mucosal and lymphatic norovirus infection. 
  • Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. 
  • Immunizations for preteens. 
  • Immuno-prophylaxis and -therapy of C-type oncorna viral diseases in mice and cats. 
  • Immunobiology of the human immunodeficiency virus envelope and its relationship to vaccine strategies. 
  • Inactivated whole SIV vaccine in macaques: evaluation of protective efficacy against challenge with cell-free virus or infected cells. 
  • Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge. 
  • Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge. 
  • Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins. 
  • Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides. 
  • Induction of cytotoxic T cell responses in newborn mice by DNA immunization. 
  • Induction of mucosal antibody responses by microsphere-encapsulated formalin-inactivated simian immunodeficiency virus in a male urethral challenge model. 
  • Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. 
  • Kaposi's sarcoma and hepatitis B vaccine. 
  • Liposomes as antigen delivery systems in viral immunity. 
  • Mammalian C-type oncorna viruses. Relationships between structural virus and cell surface antigens and their possible significance in immunological defense mechanisms. 
  • Melanoma patient antibody responses to melanoma tumor-associated antigens defined by murine monoclonal antibodies. 
  • Modified varicella-like syndrome in children previously vaccinated with live attenuated measles, mumps, rubella and varicella vaccine. 
  • Molecular analysis of adenovirus isolates from vaccinated and unvaccinated young adults. 
  • Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3. 
  • Murine granulocyte-macrophage colony-stimulating factor expressed from a bicistronic simian immunodeficiency virus-based integrase-defective lentiviral vector does not enhance T-cell responses in mice. 
  • Nasal peptide vaccination elicits CD8 responses and reduces viral burden after challenge with virulent murine cytomegalovirus. 
  • Natural immunity to HIV and its possible relationship to vaccine strategies. 
  • Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239delta3 in adult and infant rhesus monkeys. 
  • Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus. 
  • Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. 
  • Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents. 
  • Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate. 
  • Potency of a Scalable Nanoparticulate Subunit Vaccine. 
  • Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. 
  • Potential leukemia virus subunit vaccines: discussion. 
  • Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost. 
  • Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy. 
  • Progress in vaccine development against SIV and HIV. 
  • Progress in vaccines against AIDS. 
  • Prolonged clinical latency and survival of macaques given a whole inactivated simian immunodeficiency virus vaccine. 
  • Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody. 
  • Prospects for development of a vaccine against HTLV-III-related disorders. 
  • Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines. 
  • Pseudotyped viruses permit rapid detection of neutralizing antibodies in human and equine serum against Venezuelan equine encephalitis virus. 
  • Recent changes in vaccination guidelines. An update on vaccines and target population initiatives. 
  • Recent clinical progress in virus-based therapies for cancer. 
  • Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate. 
  • Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques. 
  • Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. 
  • Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. 
  • Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. 
  • Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC. 
  • Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: implications for antigen-specific immunotherapy. 
  • Resistance to infection, early and persistent suppression of simian immunodeficiency virus SIVmac251 viremia, and significant reduction of tissue viral burden after mucosal vaccination in female rhesus macaques. 
  • Retroviral E-DNA: persistence and gene expression in nondividing immune cells. 
  • Rhesus immune responses to SIV Gag expressed by recombinant BCG vectors are independent from pre-existing mycobacterial immunity. 
  • Role of HIV membrane in neutralization by two broadly neutralizing antibodies. 
  • SIV vaccine protection of rhesus monkeys. 
  • SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. 
  • Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. 
  • Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults. 
  • Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children. 
  • Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine. 
  • Simian immunodeficiency virus DNA vaccine trial in macaques. 
  • Simian immunodeficiency virus-Vpx for improving integrase defective lentiviral vector-based vaccines. 
  • Sirolimus enhances the magnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in rhesus macaques. 
  • Structural and functional features of the HIV envelope glycoprotein and considerations for vaccine development. 
  • Structural determinants of insert retention of poliovirus expression vectors with recombinant IRES elements. 
  • Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4. 
  • Studies of complement-activating antibodies in the SIV/macaque model of acute primary infection and vaccine protection. 
  • Technologies for global health. 
  • Technology evaluation: CEA-TRICOM, Therion Biologics Corp. 
  • Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. 
  • The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines. 
  • The impact of rotavirus gastroenteritis on the family. 
  • The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. 
  • The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network. 
  • Tissue plasminogen activator (tPA) signal sequence enhances immunogenicity of MVA-based vaccine against tuberculosis. 
  • Toward a vaccine against AIDS: rationale and current progress. 
  • Ultraviolet-light-inactivated Cas-Br-M murine leukemia virus induces a protective CD8+ cytotoxic T lymphocyte response in newborn mice. 
  • Understanding orthopoxvirus interference with host immune responses to inform novel vaccine design. 
  • Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection. 
  • Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660. 
  • Vaccination to Prevent Cancer. 
  • Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge. 
  • Vaccination with vif-deleted feline immunodeficiency virus provirus, GM-CSF, and TNF-alpha plasmids preserves global CD4 T lymphocyte function after challenge with FIV. 
  • Vaccine development for HIV infection. 
  • Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. 
  • Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge. 
  • Varicella during pregnancy. Maternal and fetal effects. 
  • Varicella in a susceptible pregnant woman. 
  • Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. 
  • Will antibody-dependent enhancement of HIV-1 infection be a problem with AIDS vaccines? 
  • Zika Virus: Diagnosis, Therapeutics, and Vaccine. 
  • Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. 
  • [Studies on growth conditions of EHF virus in primary rat lung cell culture]. 
• 

  Keywords of People

  • Cunningham, Coleen Kathryn, Professor of Pediatrics, Pathology
  • Ferrari, Guido, Associate Professor of Surgery, Molecular Genetics and Microbiology